Efficacy and Safety of Cabotegravir-Rilpivirine in PLWH: A Real-World Study.

ABSTRACT:

Background

Long-acting injectable antiretroviral therapy (LA-ART) with cabotegravir and rilpivirine (CAB + RPV) has emerged as a promising alternative to daily oral regimens for people living with HIV (PLWH), particularly those facing adherence challenges. While clinical trials have demonstrated its efficacy, real-world evidence remains limited.

Methods

This retrospective, multicenter study evaluated the efficacy and safety of CAB + RPV in 160 virologically suppressed PLWH across eight Italian infectious disease units. Participants received intramuscular CAB (600 mg) and RPV (900 mg) every eight weeks without an oral lead-in phase. Clinical, immunological, and biochemical parameters were assessed at baseline and after 24 weeks.

Results

At week 24, 96.25% of participan

SUBMITTER: Conti GN 

PROVIDER: S-EPMC12656754 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature